Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.39 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27140458 | 1.00 | NOTUM (0.50) | NOTUMUSP30ACKR3NPC1HDAC1 | |
| SCHEMBL27152640 | 1.00 | NOTUM (0.50) | NOTUMUSP30ACKR3NPC1HDAC1 | |
| SCHEMBL27142997 | 0.93 | CNR1 (0.48) | NOTUMUSP30NPC1CNR1 | |
| SCHEMBL27142998 | 0.93 | CNR1 (0.48) | NOTUMUSP30NPC1CNR1 | |
| SCHEMBL30781309 | 0.83 | PIM1 (0.49) | — | |
| SCHEMBL30781462 | 0.83 | PIM1 (0.49) | — | |
| SCHEMBL1027561 | 0.81 | TDP1 (0.48) | — | |
| SCHEMBL4367577 | 0.81 | TDP1 (0.48) | — | |
| SCHEMBL15093842 | 0.80 | NOTUM (0.50) | NOTUMUSP30ACKR3CNR1SMPD3 | |
| SCHEMBL1534166 | 0.78 | NOTUM (0.61) | NOTUMUSP30ACKR3HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | NOTUM 3224/4885USP30 10/4885ACKR3 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.